Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma a real-world retrospective...

Area of Science:

• Oncology
• Pharmacology

Background:

• Afatinib, a second-generation EGFR TKI, is approved for metastatic NSCLC in India.
• Real-world data on Afatinib's clinical outcomes in India is limited.

Purpose of the Study:

• To evaluate the clinical outcomes of Afatinib therapy in a real-world setting for advanced EGFR-mutant NSCLC in India.
• To assess the safety and efficacy of Afatinib in a diverse patient population.

Main Methods:

• Retrospective review of electronic medical records for 43 patients with advanced EGFR-mutant NSCLC treated with Afatinib.
• Analysis included patients receiving Afatinib as first-line therapy (n=31).

Main Results:

• Median progression-free survival (PFS) was 15.03 months (95% CI: 7.8-18.3 months).
• Overall survival (OS) was not reached at 14% maturity, with a lower 95% CI limit of 34.9 months.
• Common adverse reactions included skin rash and diarrhea, managed effectively with dose alteration.

Conclusions:

• Afatinib exhibits a manageable safety profile and comparable efficacy in real-world Indian practice.
• This is the first real-world study from India evaluating Afatinib's efficacy in advanced NSCLC.
• Afatinib represents a viable first-line treatment option alongside other EGFR TKIs for advanced NSCLC in India.